Subscribe to RSS
Greenovation Biotech GmbH
15 December 2011 (online)
Core competence of greenovation Biotech GmbH, founded in 1999, is the efficacy optimization and production of pharmaceutically highly efficient glycoproteins in contained photobioreactors.
greenovation Biotech GmbH offers products und services for the pharmaceutical industry und enterprises in the field of biotechnology. It possesses innovative technologies for production and refinement of complex pharmaceutical proteins in moss cells. Bryotechnology, developed by greenovation, is a safe and cheap platform for the therapeutic biopharmaceuticals with special features and improved efficacy, e.g., for cancer fighting antibodies.
By specific genetic modifications of the cell expression system, the sugar structures of the produced proteins can be adapted to those of the human being. This technology facilitates for the proteins produced in moss tissue wider therapy possibilities than conventional therapeutics and is up to now unique for plant production systems.
Headquartered in Heilbronn, Germany, with a branch in Freiburg, Germany, greenovation currently has eighteen employees. The scientists of greenovation are involved in several research projects funded by the German government and the European Union. greenovation also benefits from its experienced management team, which has a diverse range of expertise within the pharmaceutical industry, biotechnologycal research, and banking.
Since the beginning of the marketing two years ago, a range of customers could be gained from Asia, Europe and the USA. Due to long development times in the preclinical phases, no product of greenovation Biotech GmbH is available in clinics yet. Nevertheless, since 2006, the enterprise already has generated significant sales by production and efficacy optimization of therapeutic proteins employed in pre-clinical studies.